Intas Pharmaceuticals Elevates Global Market Position with UDENYCA® Acquisition
Intas Pharmaceuticals, through its Accord BioPharma division, acquires UDENYCA® from Coherus BioSciences, solidifying its leadership in the global biosimilar market. The acquisition extends its pegfilgrastim offerings and enhances patient care by offering multiple administration options. Over 300,000 patients have already benefited from UDENYCA® since its launch.
- Country:
- India
In a strategic acquisition, Intas Pharmaceuticals has bolstered its position in the global biosimilar market by obtaining UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This move expands Intas and its subsidiary Accord BioPharma's product lineup and enhances their leadership in both U.S. and international markets.
UDENYCA® is vital in reducing infection risks in cancer patients undergoing myelosuppressive treatments. Its availability in multiple forms—autoinjector, on-body injector, and prefilled syringe—offers flexible patient-friendly administration. To date, more than 300,000 patients have been treated with UDENYCA®, marking a significant impact on healthcare.
Beyond broadening its product range, the acquisition also infuses new talent across sales, marketing, and operational functions. Intas' strategic growth sees it as a prominent player in the biosimilar sector, promising improved patient care globally. The acquisition underscores Intas' commitment to high-quality, accessible treatments.
(With inputs from agencies.)
Google News